Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms

Journal Article · · Cancer Res.; (United States)
OSTI ID:5688017
Tumor-associated monoclonal antibodies were radiolabeled with /sup 125/I and /sup 131/I and given i.v. in pairs to 19 patients 1-26 days prior to surgical excision of primary and metastatic breast, ovarian, and gastrointestinal tumors. For individual patients each monoclonal antibody was designated as specific or nonspecific according to prior immunoperoxidase staining results on the appropriate target neoplastic tissues. Quantitation of antibody uptake was performed on resected normal and neoplastic tissues. Although good tumor:non-tumor ratios were obtained with the specific antibodies (maximal tumor:blood ratio, 35.8:1 at 12 days postadministration), the absolute amount of radiolabel detected in tumors was small (mean value of 0.015% of total injected amount per g of tumor occurring 1 day postadministration). Furthermore, both specific and nonspecific antibodies accumulated in normal lymph nodes to a significant extent (mean value of 0.0026% of total injected amount per g of tissue occurring 1 day postadministration). Knowledge of such data is essential prior to considering therapeutic uses of radiolabeled monoclonal antibodies.
Research Organization:
Royal Postgraduate Medical School, London, England
OSTI ID:
5688017
Journal Information:
Cancer Res.; (United States), Journal Name: Cancer Res.; (United States) Vol. 6; ISSN CNREA
Country of Publication:
United States
Language:
English